Compare MasterCard Inc (MA) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MasterCard Inc vs BIO-TECHNE Corp — how do they compare? MasterCard Inc trades at $564.9 (market cap $493.34B), while BIO-TECHNE Corp trades at $72.03 (market cap $11.24B). The key difference: MasterCard Inc is far larger — about 43.9× BIO-TECHNE Corp's market cap, and MasterCard Inc pays the higher dividend (0.62%). Which is the better fit depends on your goals.
| MA | TECH | |
|---|---|---|
Market Cap | $493.34B | $11.24B |
Volume | 4,635,698 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $598.96 | $72.29 |
52-Week Low | $471.55 | $43.31 |
Enterprise Value | $506.38B | $11.32B |
Dividend Yield | 0.62% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mastercard (MA) trades at $565.60, up 0.47% today, with a bullish technical signal and strong institutional interest. Recent earnings beats, robust revenue growth to $32.79B in 2025, and high profitability margins (net income margin 46.34%) underscore fundamental strength. The stock faces competition from emerging payment technologies but maintains analyst optimism with a consensus price target of $660.85.
Outlook remains positive due to consistent earnings outperformance and strategic AI initiatives, though risks include payment disruption from stablecoins and high valuation multiples. Institutional holdings increased, with 79% of analysts rating it Buy, supporting upside potential amid market volatility.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MasterCard Inc
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
